secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027449
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience Q2 2023 cash $13.3M; auditor resigns; Ovaprene Phase 3 enrollment to start 4Q23
--------------------------------------------------------------------------------

- Cash and cash equivalents of $13.3M at June 30, 2023; G&A expenses $2.9M, R&D expenses $6.0M.
- Auditor Mayer Hoffman McCann P.C. resigned effective upon filing of 2023 10-K or earlier; no disagreements; prior report had going concern paragraph.
- XACIATO first commercial sale expected 2H-2023; $1.0M cash received and $1.8M milestone upon first sale from partner Organon.
- Ovaprene pivotal Phase 3 contraceptive efficacy study enrollment to start 4Q-2023; U.S. rights licensed to Bayer.
- Sildenafil Cream 3.6% positive Phase 2b topline data; preparing end-of-Phase 2 FDA meeting for FSAD/FSIAD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/0001493152-23-027449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer